Beyond Conventional: The New Horizon of Targeted Therapy for the Treatment of Advanced Non Small Cell Lung Cancer

In the last few years the advent of targeted therapies against oncogenic drivers significantly improved the survival of non small cell lung cancer (NSCLC) patients with a favourable toxicity profile. Therefore, genetic testing, including at least EGFR mutations and ALK/ROS1 rearrangements, should be...

Full description

Saved in:

Bibliographic Details
Published in:	Frontiers in oncology Vol. 11; p. 632256
Main Authors:	Tartarone, Alfredo, Lapadula, Vittoria, Di Micco, Concetta, Rossi, Gemma, Ottanelli, Carlotta, Marini, Andrea, Giorgione, Roberta, Ferrari, Katia, Catalano, Martina, Voltolini, Luca, Mini, Enrico, Roviello, Giandomenico
Format:	Journal Article
Language:	English
Published:	Frontiers Media S.A 21-05-2021
Subjects:	genetic testing MET non small cell lung cancer oncogenic drivers Oncology targeted therapies
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	In the last few years the advent of targeted therapies against oncogenic drivers significantly improved the survival of non small cell lung cancer (NSCLC) patients with a favourable toxicity profile. Therefore, genetic testing, including at least EGFR mutations and ALK/ROS1 rearrangements, should be performed in all NSCLC patients (in particular with adenocarcinoma) who received a diagnosis of advanced disease. This review focuses on novel druggable oncogenic drivers, such as MET exon 14 mutations/MET amplification, RET fusions, BRAF V600E mutations, KRAS G12C mutations, NTRK rearrangements, and HER2 alterations.
Bibliography:	ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-3 content type line 23 ObjectType-Review-1 Edited by: Francesco Petrella, European Institute of Oncology (IEO), Italy Reviewed by: Francesco Facchinetti, Gustave Roussy Cancer Campus, France; Haiyan Tu, Guangdong Provincial People’s Hospital Lung Cancer Institute, China This article was submitted to Thoracic Oncology, a section of the journal Frontiers in Oncology
ISSN:	2234-943X 2234-943X
DOI:	10.3389/fonc.2021.632256